Cross-source identity
National Provider Identifier 1003200395 as it appears in every federal dataset Fonteum holds. Each row is a distinct public source; the chip carries the source and the snapshot date behind that field — the record-level form of the source-provenanced graph.
| Federal source | Key | What it provides | Provenance |
|---|
| CMS NPPES | NPI 1003200395 | Registry identity — psychiatrist, taxonomy 2084P0800X | Source:CMS NPPESSnapshot 2026-05-06 |
| CMS Open Payments | NPI 1003200395 | 153 industry-payment records, 2024 | Source:CMS Open PaymentsSnapshot PY2024 |
| CMS Medicare Part D | NPI 1003200395 | 34 drugs prescribed, 2024 | Source:CMS Part DSnapshot DY2024 |
| Fonteum entity graph | entity a573c4e7… | Canonical resolved node · 2 identifier(s) · 1 edge(s) | Source:Entity graphSnapshot 2026-06-11 |
Industry payments
Payments and transfers of value this clinician received from drug and device manufacturers, disclosed under the Physician Payments Sunshine Act. A payment is a disclosure, not a judgment.
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $89,358 | 33 |
| Consulting Fee | $13,723 | 3 |
| Travel and Lodging | $12,982 | 52 |
| Food and Beverage | $3,674 | 65 |
| Manufacturer | Amount | Records |
|---|---|---|
| Neurocrine Biosciences, Inc. | $90,516 | 106 |
| Otsuka America Pharmaceutical, Inc. | $23,140 | 32 |
| E.R. Squibb & Sons, L.L.C. | $5,920 |
Prescribing
Prescriptions written under Medicare Part D, aggregated by drug across the program. Totals reflect claims paid, not patients treated.
| Drug | Claims | Drug cost |
|---|---|---|
| Ingrezza(Valbenazine Tosylate) | 232 | $931,570 |
| Austedo Xr(Deutetrabenazine) | 21 | $119,305 |
| Nuplazid(Pimavanserin Tartrate) | 35 | $89,078 |
| Rexulti(Brexpiprazole) | 116 | $83,504 |
| Nuedexta(Dextromethorphan Hbr/Quinidine) | 68 | $50,075 |
Beneficiary counts below 11 are suppressed by CMS — the total shown is a lower bound.
Quality
CMS Quality Payment Program Merit-based Incentive Payment System (MIPS) final score, where this clinician participated. Absence of a score is not a quality signal — many clinicians report through a group or are exempt.
Enrollment & sanctions
Screening aid — re-confirm any match against the issuing list before acting. A clean result means no record was found in the federal OIG LEIE or the state Medicaid lists Fonteum currently holds (NY, OH, GA), not a guarantee that none exists elsewhere. Not a legal or credentialing certification.
Ownership & affiliations
One-hop relationships in the resolved entity graph — chain membership, ownership, and operation edges, each backed by a federal source row. Most individual clinicians carry none; edges populate for owners and organizations as the Lane D backfill runs.
| Relationship | Entity | Source |
|---|---|---|
| ← pays | E.R. Squibb & Sons, L.L.C. (NJ) | cms_open_payments |
| 12 |
| Acadia Pharmaceuticals Inc | $122 | 1 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | $38 | 2 |